
FDA Fast-Tracks Three Psychedelic Therapies in Historic Regulatory Shift
FDA grants priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies, marking the most significant federal psychedelic policy advancement in modern American history.

































































